news, journals and articles from all over the world.
Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Read moreThe University of Texas Health Science Center at Houston (UTHealth) has teamed up with the White House Office of Science and Technology Policy and the National Institute of Standards and Technology (NIST) to develop search engines that will help streamline COVID-19 research for health care experts fighting the virus.
Read more
From a negative pressure helmet to enhanced protocols, investigators are adapting their research to focus on the COVID-19 pandemic.
Read moreMore than 800 employees from Rutgers, Robert Wood Johnson University Hospital and University Hospital are participating in a pioneering study
Read more
Fred Hutchinson Cancer Research Center is launching a new COVID-19 research project called CovidWatch. This volunteer longitudinal study, aims to answer some of the most important questions about COVID-19
Supriya Munshaw, a senior lecturer at Johns Hopkins Carey Business School, offers insights on the likely time frame for a coronavirus vaccine, the steps involved in developing one, the most promising candidates currently in the labs of biotech companies, and why, years after the MERS and SARS outbreaks, a coronavirus vaccine still has not been produced.
Read more
Researchers at UC San Diego recently created a pharmacophore model and conducted data mining of the conformational database of FDA-approved drugs that identifies 64 compounds as potential inhibitors of the COVID-19 protease. Among the selected compounds are two HIV protease inhibitors, two hepatitis C protease inhibitors, and three drugs that have already shown positive results in testing with COVID-19.
Read moreAnswering the growing need for additional testing, and in direct response to shortages encountered in testing kit supply pipelines, the Coriell Institute for Medical Research is now offering services to create viral testing collection tubes containing different media and/or buffer formulations, for use in COVID-19 testing kits. Coriell is also exploring the feasibility of saliva as a means for testing for the new coronavirus.
Read more
The Rutgers COVID Response Pandemic Preparedness Center, which is coordinating the university’s myriad research, public health, and outreach efforts to combat COVID-19, has named Henry F. Raymond, associate professor in the department of biostatistics and epidemiology at the Rutgers School of Public Health, as it’s associate director for public health.
Read moreRush University Medical Center is participating in a new clinical trial to test the effectiveness of the drug remdesivir in the treatment of coronavirus disease 2019 (COVID-19).
Read more
Announcement from the Harrington Discovery Institute at University Hospitals of a new initiative that galvanizes its transatlantic network of academic institutions, foundations, and philanthropic partners to accelerate promising, near-term therapies to treat COVID-19 and its complications and battle future pandemic threats.
In advancing its portfolio of 120 drugs-in-the-making at 54 leading academic centers in North America and the U.K., HDI has developed a proven model that has enabled scientists in academia to accelerate their breakthrough drug discoveries toward trials in patients.
Read more